Pharmaceutical process development is how a lab-scale synthesis becomes a manufacturing process you can run again and again. It sets the route, the conditions, and the controls. The goal is simple. Every batch of an active pharmaceutical ingredient (API) should meet the same quality standard.
A reaction that works in a flask is not a manufacturing process yet. It may need too much solvent. It may use a hazardous reagent. It may depend on a purification step that cannot be done at scale. Process development fixes these problems before they become expensive.
This article explains what process development means, why it matters, how it works stage by stage, and where projects usually struggle. It also covers how a CDMO can help. The focus is on API and drug-substance development.
What Is Pharmaceutical Process Development?
Pharmaceutical process development is the work of designing, testing, and improving the method used to make a drug substance. For an API, the “process” includes every chemical step, material, piece of equipment, setting, and control involved.
The ICH Q11 guideline describes the aim. It covers approaches to developing and understanding the drug substance manufacturing process. It also explains what information to include in a regulatory submission.
In practice, process development answers questions like these:
- Which synthetic route is safest and most practical at scale?
- Which settings affect yield and purity? How much can they vary?
- How do impurities form, and how are they removed?
- What changes when batch size goes from grams to kilograms?
Process development is not formulation. It deals with how the API is made. Formulation deals with turning that API into a tablet, capsule, or injection. If you want to see how the two connect, read SCL’s guide on the journey from API to formulation.
Why Is Process Development Important in Pharmaceutical Manufacturing?
Early decisions shape everything that follows. A weak route can cause trouble in scale-up, in regulatory filing, and in commercial supply. Fixing it later costs more time and money.
Consistent product quality
Regulators expect each batch to meet its specifications. That only happens when you know which parameters drive quality and keep them under control. Say a reaction runs a few degrees too warm and a by-product doubles. You want to learn that in development, not in production.
A process that scales
Chemistry behaves differently in large vessels. Heat removal, mixing, and addition times all change. Studying these early lowers the risk of failed batches later.
Better efficiency
Higher yields, fewer steps, and less solvent reduce the cost per kilogram. These gains come from planned study, not from last-minute fixes.
Regulatory readiness
Development data supports the manufacturing sections of a filing. It shows why you chose a route, a set of ranges, and a control strategy. API manufacturing must also follow GMP principles.
What Are the Key Stages of Pharmaceutical Process Development?
Every project is different. Still, most follow the same path. The stages overlap, and teams often loop back. A finding at scale can send chemists back to an earlier step.
1. Route scouting and selection
Chemists compare possible routes to the same molecule. They look at the number of steps, starting material supply, safety, expected yield, and impurity risk. A short route is not always the best one. A longer route that is easier to control can win.
Starting material selection belongs here too. ICH Q11 gives principles for choosing and justifying starting materials for synthetic drug substances.
2. Process parameter optimization
Next, the team studies each step. They test temperature, concentration, reagent ratios, solvent, time, and pH. The aim is the best balance of yield, purity, safety, and robustness.
Many teams use design of experiments (DoE) here. It changes several variables at once in a planned way. That shows how variables interact, which one-factor-at-a-time testing misses.
ICH Q8(R2) builds on this idea. It defines a design space as the combination of input variables and process parameters shown to assure quality.
3. Impurity understanding and control
Impurities can come from starting materials, by-products, degradation, reagents, or solvents. The team finds out where each one forms. Then they decide how to prevent it, remove it, or control it with a specification.
None of this works without good analytical methods. You cannot control what you cannot measure. SCL’s article on why analytical testing matters in drug development covers this link in more detail. Analytical support is usually needed alongside process work.
4. Scale-up studies
Scale-up studies test the process in larger equipment. Teams check heat transfer, mixing, addition rates, filtration, and drying. They also test longer hold times. The point is to find differences between lab and plant before commercial batches are made.
5. Process monitoring and control
Process analytical technology (PAT) measures critical attributes while the process runs. The FDA describes its goal as better understanding and control of manufacturing through timely measurements during processing.
PAT is not needed everywhere. It helps most where a step is sensitive and real-time data can improve decisions.
6. Technology transfer
The last stage is handover. The receiving site needs clear procedures, parameter ranges, in-process controls, and specifications. A process that only its developers can run is not ready. Good documentation closes that gap.
What Are the Main Challenges in Pharmaceutical Process Development?
Some problems appear again and again. They fall into two groups.
Chemistry and quality challenges
- Impurities at scale. A minor impurity in the lab can grow in the plant. Longer reaction times and different heat profiles often cause it. High-risk impurities need extra care.
- Yield loss. Slower heat removal or weaker mixing can lower yield. Yield problems that go unnoticed can also affect supply. SCL covers this in its piece on early detection of yield challenges.
- Physical form. Crystallization conditions affect crystal form and particle size. That changes filtration, drying, and later handling. Form control should be settled during development.
- Reaction safety. Exothermic reactions and unstable intermediates may be manageable in the lab. They need a proper hazard review before scale-up.
Process and project challenges
- Narrow operating windows. If a step only works in a tight range, small changes can cause failed batches.
- Raw material variability. Different lots or suppliers can change process behavior.
- Tight timelines. Shortcuts save time early and cost more later.
- Poor documentation. Weak records make technology transfer harder.
How Does Technology Improve Pharmaceutical Process Development?
Technology does not replace chemistry knowledge. It helps teams learn more from fewer experiments.
Design of experiments and statistical analysis
DoE shows which parameters matter and how they interact. It supports the quality by design approach in ICH Q8 and Q11.
Process analytical technology
In-line and at-line probes track reaction progress or crystallization in real time. This reveals behavior that occasional sampling would miss.
Modeling and simulation
Kinetic, thermal, and mixing models can predict how a step may behave at scale. They narrow the number of experiments. Results still need checking against real data.
Parallel screening and data management
Small parallel reactors test many conditions quickly. This is useful for solvent, catalyst, and crystallization screening. Organized electronic records then make trends easier to see and transfer documents easier to build.
Use technology where it answers a real question. Adding it to a well-understood step only adds cost.
How Can a CDMO Support Pharmaceutical Process Development?
Many companies don’t have the chemists, pilot equipment, and analytical labs needed to develop an API process in-house. A CDMO can provide them. It also keeps development and manufacturing under one roof, which means fewer handoffs.
A CDMO can take on route scouting, parameter optimization, scale-up studies, and process monitoring. It can also run the analytical work that supports each of these. This lets a smaller team focus on the product and its regulatory plan.
SCL Life Sciences covers route scouting and optimization, process parameter optimization, scale-up studies, and PAT implementation. You can read the details on its process development services page. For the full range, including later-stage support, see SCL’s CDMO services.
Conclusion
Pharmaceutical process development connects a promising synthesis to dependable manufacturing. It covers route selection, parameter control, impurity management, scale-up, and documentation. The work done here decides how smooth manufacturing, filing, and supply will be later.
If you need outside support, a CDMO with development, analytical, and manufacturing capabilities can help carry a process to commercial readiness. To discuss a project, contact SCL Life Sciences.
FAQs
You can find them through CDMOs and specialist contract development providers. SCL Life Sciences offers process development services for API drug substances.
When you compare providers, check these points:
- Scope: Do they cover route scouting, parameter optimization, scale-up, and monitoring for your type of molecule?
- Analytical support: Can they handle impurity work and method development alongside process work?
- Continuity: Can development move into commercial manufacturing without a major change of team or site?
- Quality record: Ask for verifiable details, such as inspection history and regulatory filings supported.
- Communication: How will they share findings, deviations, and decisions?
- Technology transfer: How do they document and hand over process knowledge?
Process development designs and optimizes the process. Process validation confirms, with documented evidence, that the defined process consistently delivers a quality product.
Development comes first. It builds the knowledge needed to set parameters, controls, and specifications. The FDA’s Process Validation guidance describes validation in three stages: process design, process qualification, and continued process verification. Development feeds mainly into the first stage. Process performance qualification at commercial scale falls in the second.
What validation requires depends on the product, the process, and the rules in each target market. Confirm the details with your regulatory and quality teams.
References
